Results 171 to 180 of about 41,188 (289)

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, Volume 208, Issue 1, Page 116-128, January 2026.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Blood Neoplasia
Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah   +4 more
doaj   +1 more source

Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA‐matched allogeneic HSCT

British Journal of Haematology, Volume 208, Issue 1, Page 219-228, January 2026.
Summary Severe graft‐versus‐host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo‐HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)‐dosing regimens for ...
Tomotaka Suzuki, Tomoyasu Jo, Kota Yoshifuji, Tadakazu Kondo, Noriko Doki, Yoshinobu Kanda, Tetsuya Nishida, Yasushi Onishi, Noboru Asada, Takahiro Fukuda, Masashi Sawa, Yuta Hasegawa, Kentaro Serizawa, Shuichi Ota, Masatsugu Tanaka, Makoto Yoshimitsu, Yoshiko Atsuta, Junya Kanda   +17 more
wiley   +1 more source

The microenvironment in myeloproliferative neoplasm

HemaSphere, 2018
Simón Méndez-Ferrer, Claudia Korn
doaj   +1 more source

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [PDF]

, 2018
William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo, Stefan N. Constantinescu   +5 more
openalex   +1 more source

Artificial intelligence for risk assessment and outcome prediction in malignant haematology

British Journal of Haematology, Volume 208, Issue 1, Page 25-38, January 2026.
Machine learning models allow for dynamic and scalable risk stratification and outcome prediction. Different modalities of data such as electronic health records, patient genetics or laboratory results can be used as input. ML models autonomously select features weighing their prognostic value. Methods of model explainability in feature selection allow
Jan‐Niklas Eckardt, Wencke Walter, Jan Moritz Middeke, Torsten Haferlach   +3 more
wiley   +1 more source

Neutralize the neutrophils! Neutrophil β1 /β2 integrin activation contributes to JAK2-V617F–driven thrombosis [PDF]

, 2018
Barbui, De Stefano, Sands, Stephen T. Oh, Wolach   +4 more
core   +2 more sources

[Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].

, 2020
Yanhong Tan, Ning Xu, Jingyue Huang, Waner Wu, Li Liu, Lingling Zhou, Xi Liu, Congguo Yin, Dan Xu, Xiang Zhou   +9 more
openalex   +2 more sources

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms [PDF]

, 2017
Rita Assi, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jörge E. Cortes, Naveen Pemmaraju, Xuemei Wang, Graciela M. Nogueras‐González, Elias Jabbour, Prithviraj Bose, Tapan M. Kadia, Courtney D. DiNardo, Keyur P. Patel, Carlos E. Bueso‐Ramos, Lingsha Zhou, Sherry Pierce, Romany Gergis, Carla Tuttle, Gautam Borthakur, Zeev Estrov, Rajyalakshmi Luthra, Juliana E. Hidalgo‐Lόpez, Srđan Verstovšek, Naval Daver   +22 more
openalex   +1 more source

Lexicon for Clonal Hematopoiesis in Liquid Biopsy

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Historically, clonal hematopoiesis (CH) has been recognized as a confounder of cell‐free DNA (cfDNA) testing. Recent evidence now demonstrates the role of CH as a risk factor in health, generating distinct sources of cfDNA that can be leveraged for liquid biopsy diagnostics.
Robert Tell, Ahmet Zehir, Andrew T. Anfora, Gargi Basu, Michelle Beidelschies, Carolyn Compton, Stephen Cristiano, James H. Godsey, John Hu, Donald J. Johann, Marisa Juntilla, Rina Kansal, Christine Lo, Dorys Lopez Ramos, Vaidhyanathan Mahaganapathy, David Merriam, Christian Rolfo, Hugh Russell, Usha Singh, Daniel Stetson, Martin You, Lauren C. Leiman   +21 more
wiley   +1 more source